Oncology Central

What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib?


In a recent article published in Matrix Biology, M Jenkins, W Croteau, D Mullins and I described the effect of the mutant BRAFV600E inhibitor, vemurafenib/PLX4032, on collagen synthesis in melanoma cells [1]. We found that this small molecule inhibitor, which blocks the sequential MAPK, RAS, RAF, MEK, ERK signaling pathway [2–4], substantially increased the synthesis of type I collagen in several human and murine melanoma cell lines.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.